                         SEQUENCE LISTING

<110>  PhaseBio Pharmaceuticals, Inc.
       Arnold, Susan
       Prior, Christopher 
 
<120>  FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE

<130>  PHAS-024/02WO

<150>  US 61/551,506
<151>  2011-11-26

<150>  US 61/526,940
<151>  2011-08-24

<160>  12    

<170>  PatentIn version 3.5

<210>  1
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence

<400>  1

Val Pro Gly Gly 
1               


<210>  2
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence

<400>  2

Ile Pro Gly Gly 
1               


<210>  3
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa can be any naturally occurring or non-natural amino acid

<400>  3

Val Pro Gly Xaa Gly 
1               5   


<210>  4
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence

<400>  4

Ala Val Gly Val Pro 
1               5   


<210>  5
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa can be any naturally occurring or non-natural amino acid

<400>  5

Ile Pro Gly Xaa Gly 
1               5   


<210>  6
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence

<400>  6

Ile Pro Gly Val Gly 
1               5   


<210>  7
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence


<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa can be any naturally occurring or non-natural amino acid

<400>  7

Leu Pro Gly Xaa Gly 
1               5   


<210>  8
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence

<400>  8

Leu Pro Gly Val Gly 
1               5   


<210>  9
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence

<400>  9

Val Ala Pro Gly Val Gly 
1               5       


<210>  10
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence

<400>  10

Gly Val Gly Val Pro Gly Val Gly 
1               5               


<210>  11
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence

<400>  11

Val Pro Gly Phe Gly Val Gly Ala Gly 
1               5                   


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ELP component sequence

<400>  12

Val Pro Gly Val Gly Val Pro Gly Gly 
1               5                   
